• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Competitors MDCI and CDSS form cross-continental CRO partnership

Competitors MDCI and CDSS form cross-continental CRO partnership

August 30, 2010
CenterWatch Staff

U.S.-based Medical Device Consultants (MDCI), which provides contract research and regulatory consulting services to the medical device industry, has formed a strategic partnership with a former competitor, U.K.-based contract research organization (CRO) Clinical Development & Support Services (CDSS).

The partnership will allow MDCI and CDSS to support medical device clinical trials in the United States and Europe and help their clients meet both Food and Drug Administration (FDA) and European Union (EU) regulatory requirements.

The MDCI-CDSS partnership is part of a growing trend toward mid-sized CROs taking advantage of opportunities to align with partners overseas as the outsourcing market has become more competitive in recent years. Strategic partnerships and alliances allow mid-sized CROs to expand their service offerings and infrastructure while maintaining a low cost base. “This happens fairly often where, for example, a small UK CRO partners with a CRO in Poland or India,” said John Lewis, vice president of public affairs for the Association of Clinical Research Organizations (ACRO). “It is also not uncommon for even a large CRO to partner with a small CRO that has specific geographic knowledge or a therapeutic niche.”

CDSS Managing Director John Illingworth said by combining their skills and infrastructure, MDCI and CDSS can offer drug sponsors the global reach of working with a large, multinational CRO while preserving the advantages of working with a mid-size CRO. “It was clear that our combined offering allowed us to preserve all the response and personalization benefits of working with a mid-size CRO whilst offering a seamless global reach,” he said. “In a highly competitive market, success depends on enhancing both breadth and quality of offering.”

Strategic partnerships also allow small or mid-sized CROs to distinguish themselves as leaders in their niche areas while still being sensitive to price. “It is essential that small to mid-sized CROs highlight their strengths and areas of expertise,” said William A. Morton, president of Massachusetts-based MDCI. “They must, however, also be able to support or guide clients throughout the development cycle.  To do this in a cost-effective manner does require specific, complementary partnering.”

The agreement calls for expanding services through mutual referrals, coordinated sales, marketing and presentation activities. Executives from both MDCI and CDSS believe the strategic partnership will give their companies a competitive edge.

MDCI’s Morton said CDSS, which has a network of clinical research associates (CRAs) across Europe, will bring both the diversity of therapeutic experience and local regulatory knowledge to the relationship. “European medical device regulations are being upgraded but many regulations still differ from country to country.  By working with CDSS, overcoming these local hurdles is simplified,” he said.

CDSS’s Illingworth said the majority of medical device companies want to ensure that clinical trial pathways to market meet both EU and FDA requirements. “For non-U.S. companies, especially those with novel and innovative applications, the FDA pathway can often seem complex and difficult to navigate.  MDCI has a deep understanding of FDA regulations, often beyond what is available in published guidance documents, and is also well-respected by the FDA. This, coupled with CDSS’ expertise with regulations and clinical trial approvals in the EU, affords us the perfect opportunity to allow our clients to maximize their return on research investment,” he said.

 —Karyn Korieth

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing